Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1146082 | 1.00 | CXCR3 (0.39) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A | |
| SCHEMBL1144944 | 0.98 | — | — | |
| SCHEMBL1145810 | 0.91 | — | — | |
| SCHEMBL1146020 | 0.79 | — | — | |
| SCHEMBL1145760 | 0.78 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A | |
| SCHEMBL1146083 | 0.78 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A | |
| SCHEMBL1144946 | 0.76 | — | — | |
| SCHEMBL954500 | 0.75 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A | |
| SCHEMBL8184430 | 0.75 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A | |
| SCHEMBL8185904 | 0.75 | CXCR3 (0.42) | CXCR3SMN1; SMN2ALOX15ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888374-B2 | Inhibitors of c-jun N-terminal kinases | ABBOTT LABORATORIES (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | ABBVIE INC. | 2006-08-03 | — | — | US | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173050-A1 | Inhibitors of c-Jun N-terminal kinases | MAPKAPK3, MAP3K3, MAPK3 | CXCR3 2899/4885SMN1; SMN2 3026/4885ALOX15 2776/4885 |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | CXCR3 3711/4885SMN1; SMN2 2223/4885ALOX15 2958/4885 |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | CXCR3 3649/4885SMN1; SMN2 2580/4885ALOX15 2903/4885 |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | GPR119, GIPR, GCGR | CXCR3 1015/4885SMN1; SMN2 2298/4885ALOX15 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.